Search - tctmd.com

Displaying 1 - 20 of 79

Sort: Relevancy | Date

News Daily News

Side Effects of Statins Might Be Overstated: CTT Collaboration

Michael O'Riordan

February 12, 2026

News Daily News

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Todd Neale

January 05, 2026

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

Caitlin E. Cox

April 14, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Daily News

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Yael L. Maxwell

December 13, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Daily News

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Michael O'Riordan

November 07, 2024

News Features

Can ‘Body Roundness Index’ Replace BMI? That Depends, Say Experts

Michael O'Riordan

October 21, 2024

News Daily News

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Yael L. Maxwell

August 19, 2024

News Daily News

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Michael O'Riordan

July 29, 2024

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Daily News

Statins Effective For Primary Prevention in Old and Very Old

Michael O'Riordan

May 29, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Daily News

Less Is More: Lp(a) Much More Atherogenic Than LDL

Michael O'Riordan

January 16, 2024

News Daily News

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Michael O'Riordan

December 06, 2023

News Conference News AHA 2023

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Michael O'Riordan

November 13, 2023

Advertisement

Side Effects of Statins Might Be Overstated: CTT Collaboration

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Rosuvastatin Bests Atorvastatin for Reducing CVD Risk: Registry Data

Can ‘Body Roundness Index’ Replace BMI? That Depends, Say Experts

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Marked LDL Lowering With Obicetrapib in HeFH: BROOKLYN

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Statins Effective For Primary Prevention in Old and Very Old

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Less Is More: Lp(a) Much More Atherogenic Than LDL

No Safety Concerns Seen With Inclisiran in Large ORION Analysis

Large, Sustained Reductions in Lp(a) With Lepodisiran in Phase I Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content